We wish you and your loved ones a Happy, Successful and Prosperous 2012.
There seems to be a surge of positions, with many companies “moving on”
after the recession years we have just experienced.

We are proud to announce that we have just celebrated our 25th Anniversary
and we are grateful to our clients and candidates for their continues support.

Our scope of practice covers the following areas: Medical Sales Representatives,
Product Specialists, Product Managers, Pharmacists - Regulatory and Production,
CRAs, Nurse Educators and Advisors, Medical Directors, Medical Advisors,
General Managers, Business Unit Managers, CEOs.

Many of the candidates we placed in junior positions have moved up the ladder
and are now in senior management positions

Perhaps, we can do the same for you?

Visit this page to see industry news updates and we look forward to hearing
from you.

Kind Regards,
________________________________________
Eta Lyons
Tel:(021)531 3050
Mobile:083 638 9811
Email:eta@etalyons.co.za
Website:www.etalyons.co.za

Disclaimer:
The information contained in this e-mail is confidential and may be subject to legal privilege.
If you are not the intended recipient, you may not use, copy, distribute or disclose the e-mail
or any part of its contents or take any action in reliance on it. If you have received this e-mail in error, please e-mail the sender by replying to this message. Although all reasonable care is taken in transmitting this message Eta Lyons % Associates CC and/or the sender does not accept responsibility for the integrity of this communication and the Company and/or sender does not guarantee that this message and/or any attachments are free of damaging codes, viruses, errors, or interferences of any nature and/or the sender does not make any warranties in this regard whatsoever and cannot be held liable for damages incurred by the recipient and/or caused by computer viruses or in any other respect.

MEDICAL DEVICES NEWS

• New Super thin skin patch can monitor heart, muscles, nerves and
        other body functions reported in the journal, Science.

• The FDA is recommending the discontinuation of the
        ShoulderFlex massager as it has life threatening risks,
        including accidental strangulation. 

• There is a new Implant Sensor Chip to monitor tumour growth.
        This new innovation will help doctors to assess tumour growth
        and best time for surgery.  The Implant will measure oxygen in
        the surrounding tissue. As the tumour grows it takes oxygen from
        surrounding tissue. The Implant will report this.

• The first RehabRobot has been approved by the FDA and will assist
        stroke patients to rehabilitate their arms and will give real-world
        strength measurements.  This will be a valuable tool to therapists.

• Cardiac rehab patients are reported not to gain from increased
        resistance training.  This may affect Rehab programmes in future.

• Medtronic have acquired PeakSurgical and Salient .PEAK has the
        Plasmablade Cutting Technology used in Ear, Nose and Throat surgery
        as well as in Plastic and General Surgery. Salient Surgical Technologies
        is the recognised leader in haemostatic sealing of soft tissue and bone,
        including it’s TRANSCOLLATION Technology for orthopaedic, spinal,
        open abdominal and thoracic procedures.

• Convatec has announced the acquisition of the Boston Medical Devices “Inc”,
        in order to strengthen their representation in Latin America.

• FDA is planning tougher regulation on trans-vaginal mesh products.

• Alere is keen to acquire its Scottish competitor Axis-Shield. 
        Alere is a Global Diagnostics company, with the only “point of care”
        CD4 count test for HIV patients. They a have a comprehensive range of
        Diagnostic Tests

• Stryker acquires Concentric for US $135 million. Concentric make minimally
        invasive devices designed to remove clots that cause ischaemic  stroke.
        This will be a valuable addition to their Neurology range of products.

• Arthrocare Speedlock Device wins FDA approval.

• Carefusion is to supply ResMed StellarNIV (non invasive ventilation) in the US.

The information in this mailer is all taken from internet sources, newspapers and magazines.
Whilst we will take every precaution to report accurately, and will use sources which we
deem to be reliable, we cannot be held responsible for any incorrect information.

Please let us know if you do not wish to receive these mailers.
We will send them once a month with the latest news. We report headlines only,
if you wish to have more detail, please let us know.

Eta Lyons & Associates is coming up for our 25th anniversary.
We are proud of our achievements, in placing quality candidates with our
large base of  loyal clients. We provide this service with professionalism
and integrity and fully comply with the Apso Code of Ethics for the recruitment
industry. From “rookie” Representatives to Senior Medical Directors, we grow careers and grow companies.

Warmest regards,
Eta Lyons
Tel: +27 21 531 3050
Cell: +27 83 638 9811
Fax: +27 86 679 1019
Email: eta@etalyons.co.za
Unit 3 Forest Mews
Corner Lonsdale Way and Forest Drive
Pinelands
South Africa
7405

Website: www.etalyons.co.za

PHARMA NEWS:

• AstraZeneca’s Crestor fails to show benefit over Pfizer Lipitor. 

• Addex  (Swiss Biotech company) regains the rights to Parkinson’s
        drug candidates from Merck & Co, due to pipeline prioritisation.

• GlaxoSmithKline moves bidders forward in the sale of its non-core OTC products.

• Indian pharmaceuticals are now the third largest in the world and are
        poised to touch US$ 20 billion by 2015.  The country’s president Pratibha Patil
        says pharma industry needs to ensure quality.  The government, alone, cannot
        identify unscrupulous producers.  ( She was referring to the huge non- authentic drug suppliers)

• Vampire Bat Saliva used to save stroke victims.  A product: DESMOTEPLASE,
        a highly fibrin specific thrombolytic, extracted from bat saliva, has been
        found to thin blood and clots in the brain. Trials continue.

• Obese kids have more asthma flare-ups – reported in the journal of
        Allergy and Clinical Immunology.

• Arrowhead Research Scientist, Chris Anzalone, says the only robust
        R&D is happening in China. All other countries have cut budgets for R&D.

• Novartis Drug Afinitor gains EU approval, to treat patients with advanced
        neuroendocrine tumours. 

• Bayer Healthcare is to acquire Pathway Medical Technologies. 
        With this acquisition, they will be strengthening their MEDRAD interventional business. 

• Daiichi Sankyo and Ranbaxy announced a New “Social Contribution Initiative”
        They will be sponsoring Mobile Clinics in India, Cameroons and Tanzania.

• FDA approves Pfizer’s Xalkori (Crizotinib). First ever therapy targeting
        Anaplastic Lymphoma Kinase (Alk). 

• Sanofi has signed deal to sell generic of Pfizer’s Lipitor in France. 

• Astella’s clot drug has been found to be raising bleeding 2 to 4 fold
        in a mid stage clinical study of heart patients.

• Oncomed Pharm and Bayer Healthcare expand cancer stem cells collaboration
        with clinical manufacturing.

• Shanghai Pharma mulls overseas acquisitions as it plans to expand.

• Cape Town is to host the 14th annual International Generic Pharma
        Alliance Conference, at the CTICC from 1st to 3 November 2011. 
        The theme of the conference is “ Breaking the barriers to medicine”.

The information in this mailer is all taken from internet sources, newspapers and magazines.
Whilst we will take every precaution to report accurately, and will use sources which we deem
to be reliable, we cannot be held responsible for any incorrect information.

Eta Lyons & Associates is coming up for our 25th anniversary.
We are proud of our achievements, in placing quality candidates
with our large base of  loyal clients. We provide this service with
professionalism and integrity and fully comply with the Apso Code of
Ethics for the recruitment industry. From “rookie” Representatives to
Senior Medical Directors, we grow careers and grow companies.

Warmest regards,
Eta Lyons
Tel: +27 21 531 3050
Cell: +27 83 638 9811
Fax: +27 86 679 1019
Email: eta@etalyons.co.za
Unit 3 Forest Mews
Corner Lonsdale Way and Forest Drive
Pinelands
South Africa
7405

Website: www.etalyons.co.za

• FDA approves Johnson & Johnson, Bayer’s Xarelto for DVT

• The FDA on Friday approved Johnson & Johnson and Bayer’s
        Xarelto (rivaroxaban) for the prevention of deep vein
        thrombosis (DVT) in patients undergoing knee or hip
        replacement surgery. Bayer noted that Xarelto is the
        only new oral anticoagulant approved in the US for venous
        thromboembolism prophylaxis for patients undergoing knee
        or hip replacement surgery.

• Biosimilars Regulatory Update: an evolving landscape

They’re costly to develop, fraught with potential patient safety
concerns and subject to regulations that have yet to be written.
Yet for the pharmaceutical industry, biosimilar monoclonal
antibodies (mAbs) represent a potential treasure chest of new
drugs—and bigger profits for the future

• Astellas agrees to sell diabetes-related patents for $609 million

• NICE rejects Roche's Tarceva for maintenance use in lung cancer,
        despite appeal

• Pfizer and ChemRar High Tech Center Announce Plans to Explore
        Innovative Medical Research and Development Partnership in Russia

• Novartis' experimental COPD drug shows "similar efficacy" to Pfizer,
        Boehringer Ingelheim's Spiriva

• Johnson & Johnson, Gilead enter into deal to develop combination
        HIV drugs

• Takeda to buy Nycomed for 9.6 Billion Euros

• Drugmakers gear up to copy biotech drugs in U.S. - reuters.com
 
Plenty of industry players want a piece of the U.S. market for generic
versions of complex biotech drugs
 

• Roche has way to get antibody therapies into brain – past the
        blood brain barrier

• Pharmaceutical & Biotechnology Industry – Mergers and Acquisitions
        – a review of M&A from 2005 t0 2011.  A review of the recent
        acquisitions and mergers of the industry indicate the following trends:
        Consolidation in medical device, generic and consumer health segment
        of the healthcare industry. Mergers and acquisitions were successful
        if driven by a blockbuster marketed products like Lipitor
        (Pfizer- Werner Lambert), Cialis (Lilly-ICOS) and Erbitux
        (Lilly-ImClone). If a company was acquired for its R&D pipeline and
        development projects or platform technology, in majority of cases,
        the acquiring company failed to derive full benefits and most of the
        projects were later discontinued or terminated. Diversified companies
        like Roche, J&J, Abbott and Novartis with devices, generics and diagnostic
        performed better as compared to pure pharmaceutical R&D driven company like
        Pfizer and Merck. With the $68 billion bid by Pfizer for Wyeth,
        $41billion for Schering Plough by Merck and $47 billion bid by Roche
        for Genentech has given a great start to 2009 M&A activity. Sepracor
        was acquired for $2.6 billion by Dainippon Sumitomo of Japan. Novartis
        has started the year 2010 by acquiring 77% of Alcon the eye care unit
        of Nestle and has paid a total of $50 billion
        ( $ 10 billion in 2009 + $28 billion in 2010 ). Merck KGA $6 billion OPA
        for Millipore, Astellas $ 4 Bn bid for OSI pharma and Celgene acquisition
        of Abraxis for 2.9 billion bring the focus back to biotechnology. Teva buyout
        of German generic Ratiopharm for $ 5 billion once again shows the importance
        of generics. Sanofi Aventis has launched a hostile bid for Genzyme with a $ 18.5 billion
        merger offer. Vaccines are hot area with the J&J offer of $2.3 billion for
        Crucell. Pfizer has bought King pharma for 3.6 billion to dilute the impact
        of Lipitor patent expiry and get some analgesic drugs. Amgen in 2011 paid
        1 billion to acquire BioVex for its OncoVex cancer vaccine in Phase III.
        Sanofi Aventis hostile bid followed by talks resulted in takeover of Genzyme
        for 20 billion dollars in 2011. Valeant has launched a hostile bid for the takeover
        of Cephalon for $ 5.7 billion, a 27% premium to its market price. Teva has acquired
        Cephalon for $ 6.2 billion. Johnson & Johnson acquired Synthes for 21.3 billion dollars.
        Takeda has acquired Nycomed for $13,6 Billion.

Eta Lyons & Associates will reach it’s 25th Anniversary in October 2011.
From a one woman business in 1986 to a small corporate in 2011,
we have consistently met the needs of our clients in the Medical Industry.

The information in this mailer is all taken from internet sources,
newspapers and magazines. Whilst we will take every precaution to
report accurately, and will use sources which we deem to be reliable,
we cannot be held responsible for any incorrect information.
This mailer has been set up  as a bulletin board, to try and give you
a general overview of what is happening in the industry. If you want
more information on any of the items mentioned, please just reply to
this email and we will send you the article in it's entirety.

Warmest regards,
Eta

 
 
Eta Lyons
Tel: +27 21 531 3050
Cell: +27 83 638 9811
Fax: +27 86 679 1019
Email: eta@etalyons.co.za
Unit 3 Forest Mews
Corner Lonsdale Way and Forest Drive
Pinelands
South Africa
7405

Website: www.etalyons.co.za

Website: www.etalyons.co.za <http://www.etalyons.co.za>  <http://www.etalyons.co.za > > >

2500 Pharmaceutical Representatives in the USA have sued their employers (Novartis, Astra and Abbott) for overtime worked since 2001. There have been two court rulings in different States, one granting the overtime and the other not. The cases are going to be appealed. In SA, our laws are different, and overtime is only paid to those earning under the "threshold" ( R149 736 pa) rate. The payment of overtime is governed by the Basic Conditions of Employment Act. Overtime is not compulsory.

US drug spending grew 2,3% in 2010, down from 5,3 % growth in 2009. This is largely due to the increased use of generics as drugs come off patent.

Eli Lilly is developing several Diabetes compounds with Boehringer Ingelheim. This expenditure plus the cost of re-structuring has caused a significant drop in earnings for the company. 

Merck & co and Johnson & Johnson have reached a deal over the marketing of Remicade and Simponi ( Rheumatoid Arthritis drugs). Johnson & Johnson had asked for arbitration on this matter, following the Merck merger with Schering Plough.

European Medicines Agency ( EMA) has approved Boehringer Ingelheim's Pradaxa for prevention of stroke in patients with atrial fibrillation ( AF). It had already been approved in the US in October last year. It has also been approved for use in patients having hip and knee replacements for prevention of DVT. (Deep Vein Thrombosis).

Pfizer has announced positive data on it's Stage 111 trial on tofacitinib for Rheumatoid Arthritis.

Sanofi Aventis is reported to be looking at strategic alternatives to it's US Dermatology Business. Their strategy will be to concentrate on high growth areas like Diabetes, Oncology and Atrial Fibrillation

Did you know? That the first recorded drugstores were in Bagdad in 754. From there they spread throughout Arabia, the Middle East and Europe.

Eta Lyons & Associates has a Corporate Social Investment Programme geared towards improving the lives of orphans in the country. We currently support 4 Aids orphans, 2 Xhosa, 1 Sotho and 1 Zulu. The Zulu child will commence her studies at UCT next year. We have also been involved with the set up and support of a Rural Feeding Programme. As we grow, so will our support of orphans and vulnerable Children in South Africa. 

The information in this mailer is all taken from internet sources, newspapers and magazines. Whilst we will take every precaution to report accurately, and will use sources which we deem to be reliable, we cannot be held responsible for any incorrect information.

We wish you and yours a very Safe, Relaxing and Peaceful Easter Holiday!

Warmest regards,

Eta

Eta Lyons

Tel: +27 21 531 3050

Cell: +27 83 638 9811

Fax: +27 86 679 1019

Email: eta@etalyons.co.za <mailto:eta@etalyons.co.za>  <mailto:eta@etalyons.co.za > >

Pharmaceutical World News:

Sanofi Aventis has bought Biopharmaceutical company, Genzyme in a $20 billion rand deal. This is part of their expansion programme to protect future business.

Pfizer announced the sale of it's drug delivery Capsugel unit, to investment firm, Kohlberg Kravis Roberts for approximately $2.4 billion in cash.

Astra Zeneca and SKF are opening factories in Russia. This is in line with the Russian Government wanting products sold in Russia to be manufactured in Russia. The Astra Zeneca factory will cost $150 million and will be operational early in 2013.

Abbott has bought Indian generic company Piramal for a reported $3.72 billion dollars.

Large Pharma companies are reportedly looking at Indian Pharmaceutical and Biotech companies with the view to purchasing, in order to maintain their presence and future viability.

Merck Pharmaceuticals has bought specialty Ophthalmic company, Inspire, for $420 million.

New developments in the treatment of Diabetes - on the way.

Insulin inhalers
Although daily injections of insulin would still be needed, inhaled insulin is currently in clinical trials and may be headed for a fast track approval by the Food and Drug Administration (FDA). These inhalers are about the size of a flashlight and uses rapid-acting insulin. The sprayed insulin is inhaled into the mouth and coats the mouth, throat and tongue. The insulin passes quickly into the bloodstream.

Insulin Pill
The discovery of a new polymer that may allow development of an effective insulin pill was reported at a recent meeting of the American Chemical Society. When the polymer is used as a pill coating, it allows insulin to get into the bloodstream without being destroyed by the digestive system. So far it has only been tested in animals. Some experts question whether insulin in pill form will prove useful, since dosing is so critical and often variable.

Eta Lyons & Associates

Eta Lyons & Associates has 4 highly skilled and very well trained consultants inland and 2 on the coast. All our applicants are – pre-screened before interview and the utmost care is taken interviewing and checking them. We have a very high success rate in placing highly competent candidates all round the country. Many of our previous candidates are still with the same company 10 to 15 years later. Of course, they have moved up the ladder. We cover all major cities in South Africa, where our clients have representatives.

The information in this mailer is all taken from internet sources, newspapers and magazines. Whilst we will take every precaution to report accurately, and will use sources which we deem to be reliable, we cannot be held responsible for any incorrect information.

This mailer has been set up as a bulletin board, to try and give you a general overview of what is happening in the industry. If you want more information on any of the items mentioned, please just reply to this email and we will send you the article in it's entirety.

Enjoy!

Warmest regards,

Eta Lyons

2010 has rushed past at an unrelenting pace. For those of us not involved in Tourism and Travel, the World Cup provided a quieter period in an, otherwise, busy year.

 We all waved our flags and blew our Vuvuzelas in the office, specially when we made lovely placements. As I was born in Holland and still have cousins there, I was particularly excited that the Netherlands made it to the finals.

 The market has picked up significantly this year and we have had an array of varied and interesting positions. We expect to have busy months in October and November, many of  those positions to start in January, so if 2011 is your year for a new challenge, now is the time to update your CV and get the ball rolling.

 At the moment, we have a Medical Director position in Cape Town - a rare and  exciting opportunity.

For new graduates, looking to be placed in the New Year, now is the time to write a comprehensive CV, research what is required in interviews, and approach one or two really good recruitment companies  who specialise in your field of choice.

Enjoy the challenge, and treat your search for a good position as a job in itself.

Kind Regards

Eta Lyons

Medical Representatives, Medical Representative Recruitment, Surgical Sales Representives, Surgical Medical Representative Recruitment, Pharmaceutical Representatives, Pharmaceutical Representative Recruitment, Medical Device Representative, Medical Device Representative Recruitment, Regulatory Affairs Recruitment, Pharmaceutical Sales Positions, Surgical Sales Positions, Medical Representative Positions, Medical Representative Placements, Surgical Representative Placements, Medical Device Representative Placements, Regulatory Affairs Placements, Medical Director Placements, Medical Director Positions, Pharmaceutical Product Manager Placements, Pharmaceutical Product Manager Recruitment, Pharmaceutical Product Manager Positions, Medical Device Product Manager Positions, Medical Device Product Manager Recruitment, Medical Device Product Manager Placements.

I am pleased to say that there has been a definite upturn in recruitment. We are getting more job specifications in, and have some excellent UPCOMING POSITIONS FOR 2010. If you are planning to make a move early in the New Year, come and see us now. In many cases, positions come in, and the client wants CV's within a couple of days. Apply now - January appointments are made in October and November.

Our Consultants are there to consult with YOU and the client. We will advise, counsel and assist you to decide what is best for y ou. In many cases, we find Representatives applying for positions without understanding exactly what is required. For the Moms wanting to get back into the surgical field, you must be aware, you need to be scrubbed and in theatre several times a week by 07h00. Most creches only open at 07h30. Be aware of that.

Assess what is really important for you and plan a new position accordingly. There is nothing worse than being in a position that does not suit you. It is stressful and ultimately, wears down your energy and self-esteem.

There are many wonderful companies out there, but not all of them will suit YOU.

Good luck and we look forward to hearing from you.

Kind regards

Eta Lyons

Medical Representatives, Medical Representative Recruitment, Surgical Sales Representives, Surgical Medical Representative Recruitment, Pharmaceutical Representatives, Pharmaceutical Representative Recruitment, Medical Device Representative, Medical Device Representative Recruitment, Regulatory Affairs Recruitment, Pharmaceutical Sales Positions, Surgical Sales Positions, Medical Representative Positions, Medical Representative Placements, Surgical Representative Placements, Medical Device Representative Placements, Regulatory Affairs Placements, Medical Director Placements, Medical Director Positions, Pharmaceutical Product Manager Placements, Pharmaceutical Product Manager Recruitment, Pharmaceutical Product Manager Positions, Medical Device Product Manager Positions, Medical Device Product Manager Recruitment, Medical Device Product Manager Placements.

The past year has seen the recruitment industry under pressure. Indeed, many recruitment agencies have closed their doors.

In an attempt to hold on to good candidates and clients, some recruiters give the candidates and clients advice that is really self serving. To try and prevent the client and candidate from going to other recruitment companies, they promise to give special service to the candidate or client.

Sure, they will give them special service BUT, no single recruiter has all the best candidates or all the best clients. Recruiting is a personal service and, for no particular reason, some clients and candidates do not like a particular recruiter. Therefore, will not give them the opportunities.

In the past few months, we have seen clients and candidates who have missed WONDERFUL opportunities through this very practice.

My honest, heartfelt advice, if you are a candidate or a client, is to give your business to two respected recruiters, to ensure that they have covered all bases.

If your recruiter sends out your CV without telling you the name of the company and without interviewing you, they are doing you a great disservice. There is no way that they can do you justice and they will decrease your chances of getting that plum position.

Be discerning, sensible and professional in your search and you will have the success that you desire.

Good luck,

Eta Lyons

Medical Representatives, Medical Representative Recruitment, Surgical Sales Representives, Surgical Medical Representative Recruitment, Pharmaceutical Representatives, Pharmaceutical Representative Recruitment, Medical Device Representative, Medical Device Representative Recruitment, Regulatory Affairs Recruitment, Pharmaceutical Sales Positions, Surgical Sales Positions, Medical Representative Positions, Medical Representative Placements, Surgical Representative Placements, Medical Device Representative Placements, Regulatory Affairs Placements, Medical Director Placements, Medical Director Positions, Pharmaceutical Product Manager Placements, Pharmaceutical Product Manager Recruitment, Pharmaceutical Product Manager Positions, Medical Device Product Manager Positions, Medical Device Product Manager Recruitment, Medical Device Product Manager Placements.

"The companies that survive the longest are the ones that work out what they uniquely can give to the world not just growth or money but their excellence, their respect for others, or their ability to make people happy. Some call those things a soul." - Charles Handy

Compliments of the season to you. We wish you a safe, fun and happy Season. It is the time when most of us in the industry take a break and catch our breath.

This quote from Leonardo da Vinci is so true - several hundred years later. "Every now and then go away, have a little relaxation, for when you come back to your work your judgment will be surer. Go some distance away because then the work appears smaller and more of it can be taken in at a glance and a lack of harmony and proportion is more readily seen."

2010 is the year of teams, goals and success. Are you in the right team to achieve your goals, do you have the right team working with you? If not, contact us or send an updated CV. Have you set your goals for 2010 - career, personal, spiritual, relationship and sporting. If not, think about them and commit them to paper early in January. Remember, a goal that is not specific, measurable with a realistic timeline is just a dream.

We achieved most, but not all, of our goals for 2009. Our goals for 2010 are in line with our industry, the Equity goals of our clients and the career advancement of our candidates.

We have worked hard to achieve our reputation as the Leading Medical Recruitment company in South Africa, but we have our excellent candidates and clients to thank for their support.

So, A BIG THANK YOU to you. Our offices will be closed from 21 December until the 4th of January 2010.

Our clients all have my cell phone number for urgent positions all round the country. If you require help or assistance you can email me and I will reply eta@etalyons.co.za

Travel safely, rest well and have a Fabulous Festive Season.

Kind regards

Eta Lyons

Medical Representatives, Medical Representative Recruitment, Surgical Sales Representives, Surgical Medical Representative Recruitment, Pharmaceutical Representatives, Pharmaceutical Representative Recruitment, Medical Device Representative, Medical Device Representative Recruitment, Regulatory Affairs Recruitment, Pharmaceutical Sales Positions, Surgical Sales Positions, Medical Representative Positions, Medical Representative Placements, Surgical Representative Placements, Medical Device Representative Placements, Regulatory Affairs Placements, Medical Director Placements, Medical Director Positions, Pharmaceutical Product Manager Placements, Pharmaceutical Product Manager Recruitment, Pharmaceutical Product Manager Positions, Medical Device Product Manager Positions, Medical Device Product Manager Recruitment, Medical Device Product Manager Placements.

2010 with all it's hype and excitement are already underway. We have already been assigned a large number of quality positions in all major centres.

2009 was a difficult year in the recruitment field, with many positions being frozen by the Global companies either because of the recession or because of pending mergers.

Nontheless, we had a very good year, although at times, it was frustrating to our Consultants, our candidates and the Managers, who often were on the point of offering to a chosen candidate and then the position was frozen.

We placed positions ranging from Business Unit Managers, National Sales Managers, Product Managers and Regional Managers. At sales level we placed candidates in a wide range of positions from Oncology, Wound Care, Renal Dialysis, Molecular Biology, Diabetes, Orthopaedics and, of course, many GP and OTC positions.

2010 promises to be year of zip, zest and zing. The world cup in the middle of the year may prove to be a recruitment challenge for both companies and our candidates. Please approach us sooner, rather than later, so we can navigate our way round the mid-year Foodball mania. Hotel and flight bookings will be both difficult and expensive.

With our many years of experience we can promise you professionalism, confidentiality and fast and efficient service.

We wish you your own personal zip, zest and zing for a successful and satisfying 2010.

Kind regards

 Eta Lyons

We work very hard for our candidates and clients to make sure that we match the two together very carefully. I know that some candidates are frustrated at the moment because placing them seems to be taking a long time. This is very much due to the recession. Also, many of the large multinational companies have frozen their headcounts, despite the fact that their SA branches are doing very well.

There are several mergers and acquisitions in process. GlaxoSmithKline is buying Stiefel Laboratories. Mercke Sharpe and Dohme and Schering Plough are in the middle of a merger. Pfizer is in the process of buying Wyeth and in SA, Adcock Ingram have made an offer to purchase Cipla Medpro. I believe that that offer has not been accepted. We will hear more in due course.

If you are in the industry and wanting to make a move it is imperative that you send your CV and come for an interview ASAP. We do not advertise all the positions that we get in and often our clients will send us a spec on Tuesday and want to interview on Friday. If you have not been interviewed and reference checked, you may miss out on a "dream" position.

Our Johannesburg branch has a huge need for Product Managers.

We have another long weekend and short week ahead. Please drive safety and take care.

Kind regards

Eta

Medical Representatives, Medical Representative Recruitment, Surgical Sales Representives, Surgical Medical Representative Recruitment, Pharmaceutical Representatives, Pharmaceutical Representative Recruitment, Medical Device Representative, Medical Device Representative Recruitment, Regulatory Affairs Recruitment, Pharmaceutical Sales Positions, Surgical Sales Positions, Medical Representative Positions, Medical Representative Placements, Surgical Representative Placements, Medical Device Representative Placements, Regulatory Affairs Placements, Medical Director Placements, Medical Director Positions, Pharmaceutical Product Manager Placements, Pharmaceutical Product Manager Recruitment, Pharmaceutical Product Manager Positions, Medical Device Product Manager Positions, Medical Device Product Manager Recruitment, Medical Device Product Manager Placements.